- Home
- GNLX vs LUCD Comparison
GNLX vs LUCD Comparison
Compare GNLX & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- LUCD
- Stock Information
- Founded
- GNLX 2001
- LUCD 2018
- Country
- GNLX United States
- LUCD United States
- Employees
- GNLX N/A
- LUCD N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- GNLX Health Care
- LUCD Health Care
- Exchange
- GNLX Nasdaq
- LUCD Nasdaq
- Market Cap
- GNLX 128.0M
- LUCD 108.0M
- IPO Year
- GNLX 2023
- LUCD 2021
- Fundamental
- Price
- GNLX $5.85
- LUCD $1.10
- Analyst Decision
- GNLX Strong Buy
- LUCD Strong Buy
- Analyst Count
- GNLX 4
- LUCD 5
- Target Price
- GNLX $19.75
- LUCD $3.70
- AVG Volume (30 Days)
- GNLX 350.8K
- LUCD 655.3K
- Earning Date
- GNLX 11-05-2025
- LUCD 11-12-2025
- Dividend Yield
- GNLX N/A
- LUCD N/A
- EPS Growth
- GNLX N/A
- LUCD N/A
- EPS
- GNLX N/A
- LUCD N/A
- Revenue
- GNLX N/A
- LUCD $4,360,000.00
- Revenue This Year
- GNLX N/A
- LUCD $13.30
- Revenue Next Year
- GNLX N/A
- LUCD $155.58
- P/E Ratio
- GNLX N/A
- LUCD N/A
- Revenue Growth
- GNLX N/A
- LUCD 14.74
- 52 Week Low
- GNLX $1.99
- LUCD $0.75
- 52 Week High
- GNLX $8.54
- LUCD $1.80
- Technical
- Relative Strength Index (RSI)
- GNLX 45.83
- LUCD 43.33
- Support Level
- GNLX $4.34
- LUCD $1.03
- Resistance Level
- GNLX $6.12
- LUCD $1.23
- Average True Range (ATR)
- GNLX 0.85
- LUCD 0.06
- MACD
- GNLX -0.32
- LUCD -0.02
- Stochastic Oscillator
- GNLX 36.41
- LUCD 23.08
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.